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cular therapy was more frequently achieved in patients with 
proximal than distal MCA occlusions, but recanalization was 
associated with favorable outcome only in M1 and proximal 
M2 occlusions. Outcome was better with distal than proxi-
mal occlusions. This study shows that recanalization can be 
used as a surrogate marker for clinical outcome only in pa-
tients with proximal occlusions.  © 2015 S. Karger AG, Basel 
 Introduction 
 Since the first successful local intra-arterial thrombo-
lysis (IAT) in a patient with basilar artery occlusion in 
1981  [1] , several randomized trials showed a benefit of 
intravenous thrombolysis (IVT) or IAT  [2–11] . The effi-
cacy of IVT or IAT in dependence of the occluded vessel 
has not been addressed in major IVT trials like Atlantis, 
European Cooperative Acute Stroke Study (ECASS) and 
National Institutes of Neurological Disorders and Stroke 
(NINDS). In a majority of IAT trials, the occlusion loca-
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 Abstract 
 Background: The aim of this study was to analyze the influ-
ence of the location of middle cerebral artery (MCA) occlu-
sion on recanalization, complications and outcome after en-
dovascular therapy.  Methods: Four-hundred sixty-four pa-
tients with acute MCA occlusions were treated with 
endovascular therapy.  Results: Two-hundred ninety-three 
patients had M1 occlusions, 116 had M2, and 55 had M3/4 
occlusions. Partial or complete recanalization was more fre-
quently achieved in M1 (76.8%) than in M2 (59.1%) or M3/4 
(47.3%, p < 0.001) occlusions, but favorable outcome (modi-
fied Rankin Scale 0–2) was less frequent in M1 (50.9%) than 
M2 (63.7%) or M3/4 (72.7%, p = 0.018) occlusions. Symptom-
atic intracerebral hemorrhage (ICH) did not differ between 
occlusion sites, but asymptomatic ICH was more common in 
M1 (22.6%) than in M2 occlusions (8.6%, p = 0.003). Recana-
lization was associated with favorable outcome in M1 (p < 
0.001) and proximal M2 (p = 0.003) but not in distal M2 or 
M3/4 occlusions.  Conclusions: Recanalization with endovas-
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tion was categorized into the major vessel territories: 
 basilar artery, internal carotid or middle cerebral artery 
(MCA). Several studies found differences in recanaliza-
tion and clinical outcome between patients with occlu-
sions of these territories  [12–15] .
 Until now, no large randomized IVT trial and only a 
small number of observational IVT studies analyzed the 
occlusion site along the MCA with regard to outcome. 
These studies found poorer outcomes in proximal occlu-
sions and better recanalization in distal occlusions  [15–
18] . Four recent randomized controlled trials showed a 
clear superiority of endovascular treatment over standard 
treatment; these studies mainly included patients with 
ICA- and M1-occlusions, and the proportion of patients 
with M2 occlusion was small (4–14%). There is ongoing 
debate whether endovascular treatment is also efficacious 
in M2-occlusions or more in distal occlusions  [19–31] .
 The aim of this study was to analyze the impact of the 
MCA occlusion site on recanalization and outcome after 
endovascular therapy for acute ischemic stroke.
 Patients and Methods 
 Patients 
 From May 1992 to May 2011, we prospectively acquired data 
of 464 patients with acute ischemic stroke with occlusions of the 
MCA who received endovascular treatment at our center. During 
the same period, 103 patients with occlusions of the MCA were 
treated with IVT. Some data from these patients were previously 
reported  [24–26, 32] .
 All patients were examined by a neurologist immediately after 
admission to the emergency room. Neurologic deficits were scored 
using the National Institutes of Health Stroke Scale (NIHSS)  [33] . 
Demographic and clinical data were recorded (age, gender, premed-
ication, time of symptom onset, coronary artery disease, atrial fibril-
lation, hypertension, diabetes, current cigarette smoking, hypercho-
lesterolemia, history of transient ischemic attack (TIA) or ischemic 
stroke, family history of TIA and stroke). The decision for treating 
with IVT and/or endovascular therapy was made on an individual 
basis. In general, within 4.5 h of symptom onset IVT was performed 
followed by IAT in the case of persisting vessel occlusion; after 4.5 h 
direct IAT was performed if: (1) diagnosis of ischemic stroke was 
established; (2) baseline NIHSS score was  ≥ 4 points or isolated apha-
sia or hemianopia was present, or in case of recurrent neurological 
deficits with a persistent major vessel occlusion; (3) hemorrhage on 
cranial CT or MRI was excluded; (4) MCA occlusion correlated with 
the neurological deficit; (5) MCA occlusion was judged to be endo-
vascularly accessible; (6) symptom duration was not longer than 6 h; 
or (7) no individual clinical or premorbid conditions or laboratory 
findings advised against thrombolysis. Digital subtraction angiogra-
phy was performed via a transfemoral approach using a biplane, 
high-resolution angiography system and all patients underwent 
complete 4-vessel cerebral angiography. All procedures were per-
formed by 4 fully trained interventional neuroradiologists. The site 
of the artery occlusion was categorized. Collaterals were classified 
as: none; moderate if minimal leptomeningeal anastomoses were 
visualized and no or minimal filling of the occluded vessel territory 
was seen; good, if leptomeningeal anastomoses filled the occluded 
vessel territory by more than half. The interventional neuroradiolo-
gist and neurologist decided on the use of urokinase and or me-
chanical intervention. At the end of angiography, recanalization was 
classified by the treating neuroradiologist according to thrombolysis 
in myocardial infarction (TIMI) grades  [34] and was prospectively 
assessed and entered into our database. Since the introduction of the 
thrombolysis in cerebral infarction (TICI) score, all recanalization 
results are also assessed according to TICI grades, but were not used 
for evaluation in this long-term study.
 A repeat CT or MRI scan was generally obtained after 24 h but 
never later than 72 h after treatment, and was performed again in 
cases of clinical deterioration. Symptomatic and asymptomatic 
 intracerebral hemorrhages (ICH) were graded according to the 
PROACT II criteria  [35] . Secondary preventive treatment was giv-
en according to current evidence and European guidelines  [36, 37] . 
Clinical outcome was assessed 3 months after the stroke using the 
modified Rankin Scale (mRS)  [38] .
 Statistical Analysis 
 Statistical analyses were performed using SPSS 21 (SPSS Inc., 
Chicago, Ill., USA). Categorical variables were compared with χ 2 
and Fisher’s exact test as appropriate, and continuous variables 
were analyzed with the Mann–Whitney test. Outcome was dichot-
omized into favorable (mRS 0–2) or poor (mRS 3–6) clinical out-
come. Recanalization was dichotomized into poor (TIMI 0–1) or 
good (TIMI 2–3). Forward stepwise logistic regression including 
all variables with p < 0.2 in univariate analyses (age, gender, NIHSS 
score on admission, time from symptom onset to treatment, atrial 
fibrillation, diabetes, hypertension, hypercholesterolemia, previ-
ous stroke, smoking, TOAST (the Trial of Org 10172 in Acute 
Stroke Treatment), occlusion site as categorical variable, recanali-
zation, symptomatic ICH) were used to determine the predictors 
of bleeding complications and outcome. A p value of <0.05 was 
considered significant.
 Results 
 Of 464 patients with MCA occlusions, 293 had an oc-
clusion in the M1, 116 in the M2 and 55 in the M3/4 seg-
ment. Of the patients with M2 occlusions, 83 had a proxi-
mal and 14 a distal occlusion of the M2 segment. A second 
vessel occlusion was found in 7.8% of the M1 occlusions 
(4 patients with additional distal MCA occlusions, 17 with 
ACA occlusions, one with vertebral artery and one with 
posterior cerebral artery occlusion), 6% of the M2 occlu-
sions (6 with ACA occlusions, one with vertebral artery 
occlusion) and 7.3% of the M3/4 occlusions (one with ad-
ditional distal MCA occlusion, 3 with ACA occlusions).
 Baseline characteristics, risk factors and treatment 
 details are given in  table 1 . Median baseline NIHSS in M1 
occlusions was 16, which was significantly higher than in 
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M2 (12, p < 0.001) or M3/4 (10, p < 0.001) occlusions, 
whereas NIHSS in M2 and M3/4 occlusions did not differ 
significantly. There was a trend toward a higher median 
baseline NIHSS in proximal compared to distal M2 seg-
ment occlusions (12 vs. 7, p = 0.067). Collateral circula-
tion in M1 occlusions was better than in M2 (p < 0.001) 
or M3/4 (p = 0.012) occlusions ( table 1 ). Mechanical tech-
niques were more often used in proximal occlusions and 
M3 occlusions were only treated medically (p < 0.001). 
Recanalization rates, outcome and bleeding complica-
tions for the different vessel segments are listed in  table 2 
and illustrated in  figure 1 .
 Successful recanalization (TIMI 2–3) was more fre-
quently observed in M1 occlusions (76.8%) than in M2 
(59.1%, p = 0.001) or M3/4 (47.3%, p < 0.001) occlusions. 
The occlusion site was the only independent predictor 
of  successful recanalization in multivariable regression 
analysis (p < 0.001).
 Favorable 3-month outcome was achieved in 145 of 
285 (50.9%) M1 occlusions, 72 of 113 (63.7%) M2 and 40 of 
55 (72.7%) M3/4 occlusions indicating that 3-month favor-
able outcome was worse in M1 compared to M2 (p = 0.025) 
or M3/4 (p = 0.003) occlusions. The occlusion site was an 
independent predictor of favorable outcome in multivari-
able regression analysis (p = 0.019; other predictors: age: 
p < 0.001, OR 0.954, 95% CI 0.936–0.972; baseline NIHSS: 
p < 0.001, OR 0.879, 95% CI 0.839–0.921); diabetes melli-
tus: p = 0.005, OR 0.392, 95% CI 0.205–0.751; hypercholes-
terolemia: p = 0.001, OR 2.229, 95% CI 1.400–3.547; recan-
alization: p < 0.001, OR 4.051, 95% CI 2.414–6.799; collater-
als: p = 0.021, OR 1.490, 95% CI 1.062–2.091; symptomatic 
ICH: p = 0.001, OR 0.027, 95% CI 0.003–0.223).
Table 1.  Baseline characteristics of 464 patients treated with IAT
M1 M2 M3/4
Number 293 116 55
Age, years, SD 64.9 (13.8) 63.7 (13.6) 65.2 (12.4)
Female, sex, mean 50.2 38.8 43.6
Vascular risk factors, % (n/N)
Diabetes mellitus 14.0 (41/293) 23.5 (27/115) 5.5 (3/55)
Hypertension 58 (179/293) 64.3 (74/115) 67.3 (37/55)
Current smoking 16.5 (48/291) 27 (31/115) 25.5 (14/55)
Hypercholesterolemia 50.3 (147/292) 54.4 (62/114) 38.2 (21/55)
Coronary artery disease 25 (73/292) 14.9 (17/114) 16.4 (9/55)
Atrial fibrillation 41.3 (116/283) 37.7 (43/114) 29.1 (16/55)
Previous stroke 7.8 (23/293) 9.6 (11/115) 12.7 (7/55)
Baseline NIHSS, median, range 16 (3–36) 12 (0–25) 10 (3–22)
Second occlusion site, %, range 7.8 (23/293) 6 (7/116) 7.3 (4/55)
IAT type, %, range
Urokinase only 59.4 (174/293) 77.6 (90/116) 100 (55/55)
Mechanical only 9.6 (28/293) 6 (7/116) 0
Both 31.1 (91/293) 16.4 (19/116) 0
Minutes from symptom onset to treatment, median (range) 249 (16–943) 275 (19–610) 278 (77–408)
Urokinase dose, median IE, range 106 (0–106) 106 (0–106) 8 × 105 (2.5 × 104–8 × 105)
Collaterals none or bad (0), %, range 16.5 (47/284) 15 (17/113) 28.3 (15/53)
Middle (1), %, range 42.6 (121/284) 68.1 (77/113) 50.9 (27/53)
M1 M2 M3/4 p value
Recanalization TIMI 2–3 76.8 (225/293) 59.1 (68/115) 47.3 (26/55) <0.001
Outcome mRS 0–2 50.9 (145/285) 63.7 (72/113) 72.7 (40/55) 0.018
Survival 82.5 (235/285) 84.1 (95/113) 96.4 (53/55) NS
Symptomatic ICH 4.5 (13/292) 6.9 (8/116) 3.6 (2/55) NS
Asymptomatic ICH 22.6 (66/292) 8.6 (10/116) 9.1 (5/55) 0.003
Table 2.  Recanalization, outcome and com-
plications (p values: results of multivariable 
regression analysis, NS: not significant)
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 Two hundred thirty-five of 285 (82.5%) patients with 
M1 occlusions, 95 of 113 (84.1%) patients with M2, and 53 
of 55 (96.4%) patients with M3/4 occlusions survived. Sur-
vival at 3 months differed significantly between M1 and 
M3 (p = 0.007) but not between M1 and M2 (p = 0.769) 
occlusions. The occlusion site was not an independent 
predictor of survival (p = 0.124; predictors: age: p < 0.001, 
OR 0.928, 95% CI 0.901–0.957; baseline NIHSS: p = 0.001, 
OR 0.923, 95% CI 0.880–0.968: collaterals: p < 0.001, OR 
2.200, 95% CI 1.457–3.321; symptomatic ICH: p < 0.001; 
OR 0.063, 95% CI 0.021–0.188; diabetes mellitus: p = 
0.047, OR 0.507, 95% CI 0.259–0.992). Symptomatic ICH 
was noted in 13 of 292 (4.5%) M1, 8 of 116 (6.9%) M2 and 
2 of 55 (3.6%) M3/4 occlusions and there was no signifi-
cant difference of the ICH rates among the occlusion 
sites (p = 0.526). Asymptomatic ICH was more frequently 
seen in M1 (22.6%) than in M2 (8.6%, p = 0.001) and in 
M3/4 (9.1%, p = 0.027) occlusions. The occlusion site was 
an independent predictor of asymptomatic ICH in multi-
variable regression analysis (p = 0.003; other predictors: 
atrial fibrillation: p = 0.017, OR 1.849, 95% CI 1.117–3.061; 
smoking: p = 0.014, OR 0.332, 95% CI 0.138–0.801). The 
rate of asymptomatic ICH did not differ significantly be-
tween proximal (9.6%) or distal (7.1%) M2 occlusions.
 Recanalization was associated with favorable outcome 
in M1 (p < 0.001) and proximal M2 occlusions (p = 0.003) 
but not in distal M2 (p = 0.505) or M3/4 (p = 1.0) occlu-
sions.
 Finally, the influence of stroke etiology based on the 
TOAST classification was not significantly different with 
regard to outcome, recanalization or bleeding complica-
tions.
 Discussion 
 The main finding of this study is that recanalization 
and outcome of MCA occlusions after endovascular ther-
apy critically depend upon the occlusion site within the 
vessel. In our series, best recanalization rates were ob-
served in proximal (M1) and worst rates in distal (M3/4) 
MCA occlusions. Nevertheless, 3-month clinical out-
come was worse in M1 compared to M2 or M3/4 occlu-
sions. Recanalization was associated with favorable out-
come in M1 and proximal M2 occlusions but not in distal 
M2 or M3/4 occlusions.
 We treated 293 patients with M1, 116 patients with 
M2, and 55 patients with M3/4 occlusions with endovas-
cular procedures. NIHSS scores were significantly dif-
ferent for different occlusion sites. In M1 occlusions, we 
found a median NIHSS of 16, in M2 of 12, and in M3/4 
of 10 points. Collaterals were generally better in proxi-
mal than in distal occlusions, most likely because only 
few  leptomeningeal collaterals can supply blood to the 
non-perfused tissue in peripheral occlusions and more 
collateral systems can compensate for proximal occlu-
sions.
 Recanalization 
 Some trials using IVT reported recanalization rates 
according to occlusion sites ranging from 30 to 65% 
for M1 and 32 to 76% for M2 occlusions  [15–18] . One 
study found a recanalization rate of 66% in M3/4 occlu-
sions  [16] . In endovascular treatment, only a few au-
thors reported recanalization rates for different sites of 
MCA occlusions. In the MERCI and Multi-MERCI tri-
mRS 0–1 mRS 0–2 Survival TIMI 2–3 Collaterals good
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 Fig. 1. Collaterals, recanalization rate and 
clinical outcome at 3 months. 
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als, better recanalization rates were reported in M2 
compared to M1 occlusions (82.1 vs. 60%)  [19] .
 In contrast to these reports of better recanalization in 
distal occlusions, in our cohort, we observed a TIMI 2–3 
recanalization more frequently in M1 (76.8%) than in M2 
(59.1%) or M3/4 occlusions (47.3%). The occlusion site 
was the only factor associated with recanalization in 
 multivariable regression analysis (p < 0.001). The tech-
niques used in our series might account for this differ-
ence. When thrombus aspiration techniques and stent 
retrievers are used as in our series, proximally occluding 
thrombi are more easily accessible for extraction than 
 distally located clots. Comparison of the favorable recan-
alization rates in proximal occlusions in our series with 
published rates after IVT support the proposal that endo-
vascular therapy might be advantageous over IVT, espe-
cially in proximal occlusions. The poorer outcome in pa-
tients with proximal vessel occlusion despite higher re-
canalization rates in our study may be due to the fact 
that more proximal occlusions lead to larger areas of hy-
poperfused tissue and higher NIHSS scores. All reperfu-
sion treatments require time for complete recanalization; 
the affected tissue may either recover or be irreversibly 
damaged.
 Outcome and Complications 
 Several trials reported outcome after IVT according to 
the MCA occlusion site  [15–18, 39] . mRS 0–1 outcome at 
3 months ranged from 24% with proximal to 52% with 
distal occlusions  [15] . Bhatia et al. [39] found favor-
able outcomes (mRS 0–2) at 3 months in 60% of M1 and/
or proximal ICA occlusions and in 77% of M2 occlu-
sions. For endovascular treatment, the MERCI and multi 
 MERCI trials achieved 33.3% favorable outcomes (mRS 
0–2) with M1 and 40.7% with M2 occlusions  [19] . In 
SWIFT PRIME, only 6 of 94 patients (6%) treated with 
IVT had M2 occlusion and 13 of 93 patients (14%) treat-
ed with stent retriever plus IVT had M2 occlusion  [27] . 
In this small subgroup of M2 occlusions, the authors re-
ported a trend toward a more favorable clinical outcome 
in the stent retriever group (RR 1.35, 95% CI 0.41–4.41). 
In the larger subgroup with M1 occlusions (n  = 133), 
there was a significantly better clinical outcome in the en-
dovascular group RR 1.74, 95% CI 1.23–2.46) in favor of 
the endovascular group  [27] . In MR CLEAN, EXTEND-
IA, ESCAPE and REVASCAT, outcome and complica-
tions were not separately reported for M2 occlusion be-
cause of the small sample sizes of this subgroup  [28–31] .
 In our series, results ranged from 51% favorable out-
comes with M1 occlusions, 64% with M2, and 73% with 
M3/4 occlusions ( table 2 ). The occlusion site was an in-
dependent predictor of outcome also in multivariable re-
gression analysis (p = 0.018). Additionally, we observed a 
trend toward favorable outcome in distal compared to 
proximal M2 occlusions (85.7 vs. 64.4%).
 The observed survival rates are similar to those report-
ed by Shi et al. [19] (67.1% in M1 and 74.1% in M2 occlu-
sions), when taking into consideration the higher NIHSS 
baseline in their cohort. Survival at 3 months differed sig-
nificantly between M1 and M3, but not between M1 and 
M2 occlusions, and not between the different M2 occlu-
sion locations.
 This study showed an association of outcome with 
 successful recanalization in M1 and proximal M2 occlu-
sions but not in distal M2 or M3/4 occlusions. This result 
is in line with 2 other trials, which found a significant as-
sociation between recanalization and outcome in M1 but 
not M2 occlusions  [13, 19] . To our knowledge, differ-
ences between proximal and distal M2 occlusions have 
not been previously reported. That recanalization was 
not associated with outcome in distal M2 or M3/4 occlu-
sions might be attributable to a methodological problem. 
Patients with distal M2 or M3/4 occlusions frequently 
show only minor neurological deficits, and the mRS may 
not be sensitive enough to detect these minor deficits. 
Changes in the NIHSS score might detect differences in 
outcome in patients with minor neurological deficits. 
However, we did not assess NIHSS score at 3 months in 
all patients.
 Complications 
 Symptomatic ICH did not differ between the occlusion 
sites. However, the number of patients with ICH was 
quite small in each group, making final conclusions dif-
ficult. Asymptomatic ICH was more frequent in M1 
(22.6%) than in M2 (8.6%) occlusions (p = 0.003). The 
existence of atrial fibrillation and non-smoking were in-
dependent predictors of asymptomatic ICH. The size of 
the infarct and a larger territory of reperfusion are pos-
sible explanations for the association of an ICH with 
proximal occlusions. It appears that there might be a pro-
tective effect of smoking against an ICH, which could be 
explained by increased plasminogen activator inhibitor-1 
production in smokers  [40] .
 Limitations 
 Our study has the inherent limitations of selection bias 
of a non-randomized single center study. In addition our 
data were analyzed retrospectively, though prospectively 
collected and recorded in our database. The data were 
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collected over 2 decades and the evolution of mechanical 
recanalization techniques and general acute care (like 
stroke unit treatment, early rehabilitation, fast etiological 
workup) of stroke patients might have influenced our re-
sults. In addition, patients' selection for endovascular 
treatment was made on an individual basis, which might 
contribute to a selection bias.
 Conclusions 
 Our results suggest that recanalization, outcome and 
complications depend critically upon the occlusion site 
within the MCA. Successful recanalization seems to be 
decisive for reaching favorable outcome, especially in M1 
and proximal M2 occlusions, which may be predomi-
nantly explained by the less severe pre-treatment neuro-
logical deficits in more distal occlusions.
 Therefore, results of revascularization studies may be 
influenced by summarizing all MCA occlusion types in 
one group, as was performed in most previous IAT trials 
(e.g. Melt, PROACT 1–2, Penumbra Pivotal Trial). Fu-
ture trials of endovascular treatment of MCA occlusions 
should take these differences between recanalization 
and clinical outcome according to the MCA vessel seg-
ments into account for patient selection and stratified 
randomization. Analyses of the location of MCA occlu-
sions are especially crucial when recanalization is used 
as a surrogate marker for clinical outcome.
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